Technical Analysis for SBPH - Spring Bank Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.57 -6.05% -0.23
SBPH closed down 6.05 percent on Tuesday, September 17, 2019, on 46 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SBPH trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
20 DMA Resistance Bearish -6.05%
Pocket Pivot Bullish Swing Setup -6.05%
Fell Below 20 DMA Bearish -5.80%
Upper Bollinger Band Touch Strength -10.75%
Shooting Star Candlestick Bearish -10.30%
Lizard Bearish Bearish Day Trade Setup -10.30%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -10.30%
Doji - Bearish? Reversal -10.30%
Upper Bollinger Band Touch Strength -10.30%

Older signals for SBPH ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of a class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that are design to target and modulate the activity of specific proteins implicated in various disease states. The company's lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops preclinical product candidates, such as SB 9400, SB 9941 and SB 9946 for RNA viral diseases. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Milford, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Disease Specialty Drugs Chronic Hepatitis B Virus Human Orthopneumovirus Preclinical Preclinical Product
Is SBPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.0
52 Week Low 3.53
Average Volume 45,419
200-Day Moving Average 7.5393
50-Day Moving Average 4.2095
20-Day Moving Average 3.816
10-Day Moving Average 3.819
Average True Range 0.263
ADX 19.03
+DI 15.0979
-DI 21.6989
Chandelier Exit (Long, 3 ATRs ) 3.4895
Chandelier Exit (Short, 3 ATRs ) 4.319
Upper Bollinger Band 4.089
Lower Bollinger Band 3.543
Percent B (%b) 0.05
BandWidth 14.308176
MACD Line -0.1085
MACD Signal Line -0.1265
MACD Histogram 0.018
Fundamentals Value
Market Cap 45.33 Million
Num Shares 12.7 Million
EPS -2.50
Price-to-Earnings (P/E) Ratio -1.43
Price-to-Sales 0.00
Price-to-Book 4.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.89
Resistance 3 (R3) 3.92 3.84 3.83
Resistance 2 (R2) 3.84 3.76 3.83 3.81
Resistance 1 (R1) 3.71 3.71 3.67 3.68 3.80
Pivot Point 3.63 3.63 3.61 3.62 3.63
Support 1 (S1) 3.50 3.55 3.46 3.47 3.34
Support 2 (S2) 3.42 3.50 3.41 3.33
Support 3 (S3) 3.29 3.42 3.31
Support 4 (S4) 3.26